AIBioTech Receives Subcontract Award From DynPort Vaccine Company LLC, for Continued Development and FDA Approval of a Nerve Agent Prophylactic
5/23/2013 9:33:02 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
RICHMOND, Va., May 23, 2013 (GLOBE NEWSWIRE) -- AIBioTech is pleased to announce receipt of a firm fixed price subcontract from DynPort Vaccine Company LLC (DVC), a CSC company, valued at nearly $3 million for laboratory studies to support development of a biologic intended for use prior to an exposure to nerve agents. DVC issued this subcontract under its prime contract number W911QY-13-C-0056 with the U.S. Department of Defense.
Help employers find you! Check out all the jobs and post your resume.
comments powered by